Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Raffeld Website

Mark Raffeld, M.D.

Selected Publications

1)  Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre Sanchez GA, Tenbrock K, Wittkowski H, Jones OY, Kuehn HS, Lee CC, DiMattia MA, Cowen EW, Gonzalez B, Palmer I, DiGiovanna JJ, Biancotto A, Kim H, Tsai WL, Trier AM, Huang Y, Stone DL, Hill S, Kim HJ, St Hilaire C, Gurprasad S, Plass N, Chapelle D, Horkayne-Szakaly I, Foell D, Barysenka A, Candotti F, Holland SM, Hughes JD, Mehmet H, Issekutz AC, Raffeld M, McElwee J, Fontana JR, Minniti CP, Moir S, Kastner DL, Gadina M, Steven AC, Wingfield PT, Brooks SR, Rosenzweig SD, Fleisher TA, Deng Z, Boehm M, Paller AS, Goldbach-Mansky R.
Activated STING in a vascular and pulmonary syndrome.
N. Engl. J. Med. 371: 507-18, 2014.
2)  Tabe Y, Jin L, Konopleva M, Shikami M, Kimura S, Andreeff M, Raffeld M, Miida T.
Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma.
Acta Haematol. 131: 59-69, 2014.
3)  Park KS, Raffeld M, Moon YW, Xi L, Bianco C, Pham T, Lee LC, Mitsudomi T, Yatabe Y, Okamoto I, Subramaniam D, Mok T, Rosell R, Luo J, Salomon DS, Wang Y, Giaccone G.
CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
J. Clin. Invest. 124: 3003-15, 2014.
4)  Nicolae A, Xi L, Pittaluga S, Abdullaev Z, Pack SD, Chen J, Waldmann TA, Jaffe ES, Raffeld M.
Frequent STAT5B mutations in ?d hepatosplenic T-cell lymphomas.
Leukemia. 2014.
5)  Masaki T, Wang Y, DiGiovanna JJ, Khan SG, Raffeld M, Beltaifa S, Hornyak TJ, Darling TN, Lee CC, Kraemer KH.
High frequency of PTEN mutations in nevi and melanomas from xeroderma pigmentosum patients.
Pigment Cell Melanoma Res. 27: 454-64, 2014.
6)  Legrand F, Tomasevic N, Simakova O, Lee CC, Wang Z, Raffeld M, Makiya MA, Palath V, Leung J, Baer M, Yarranton G, Maric I, Bebbington C, Klion AD.
The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders.
J. Allergy Clin. Immunol. 133: 1439-47, 1447.e1-8, 2014.
7)  Gläsker S, Smith J, Raffeld M, Li J, Oldfield EH, Vortmeyer AO.
VHL-deficient vasculogenesis in hemangioblastoma.
Exp. Mol. Pathol. 96: 162-7, 2014.
8)  Venkataraman G, Song JY, Tzankov A, Dirnhofer S, Heinze G, Kohl M, Traverse-Glehen A, Eberle FC, Hanson JC, Raffeld MA, Pittaluga S, Jaffe ES.
Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival.
Blood. 121: 1795-804, 2013.
9)  Huppmann AR, Roullet MR, Raffeld M, Jaffe ES.
Angioimmunoblastic T-cell lymphoma partially obscured by an Epstein-Barr virus-negative clonal plasma cell proliferation.
J. Clin. Oncol. 31: e28-30, 2013.
10)  Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN.
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma.
Clin. Cancer Res. 19: 2048-60, 2013.
Click Here to View Expanded Bibliography.

This page was last updated on 8/13/2014.